Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT03455868
Other study ID # MP-10-2018-2957
Secondary ID
Status Recruiting
Phase
First received
Last updated
Start date March 15, 2018
Est. completion date December 1, 2025

Study information

Verified date February 2024
Source CHU de Quebec-Universite Laval
Contact Sarah Chouinard-Castonguay
Phone 4185254444
Email Sarah.Chouinard-Castonguay@crchudequebec.ulaval.ca
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

Background: Bone fragility is a complication of type 2 diabetes. Diabetes treatments may ameliorate or deteriorate bone fragility in this population. Bariatric surgery is gaining in popularity in people with type 2 diabetes and may impact bone health. Objectives: To evaluate the impact of the most popular bariatric procedure worldwide (sleeve gastrectomy (SG)) on vBMD by QCT in patients with type 2 diabetes; Secondary aims: (1) to identify the determinants of vBMD after bariatric surgery in patients with type 2 diabetes; (2) to compare vBMD and its potential determinants after bariatric surgery with obese controls without diabetes as well as with controls without obesity and normoglycemia.


Description:

This is a multicentre, prospective and observational study comprising a bariatric group with or without diabetes undergoing SG (n=70) and one control group (n=30). Outcome measures are assessed before and at 4 months, 8 months, one year and 3 years after surgery in the bariatric groups and at a single visit for the control group. Bariatric groups will include adult men and women with or without type 2 diabetes and obesity undergoing sleeve gastrectomy and followed at 0, 4 months, 8 months, 1 year and 3 years after surgery, and the control group will consist of 30 overweight individuals (10 men, 10 premenopausal women, 10 menopausal women) and without diabetes or prediabetes and assessed at a single visit.


Recruitment information / eligibility

Status Recruiting
Enrollment 100
Est. completion date December 1, 2025
Est. primary completion date December 1, 2024
Accepts healthy volunteers Accepts Healthy Volunteers
Gender All
Age group 18 Years to 60 Years
Eligibility Inclusion Criteria: - bariatric groups: men and women; 18 to 60 years old; with a BMI >=35 kg/m2; with type 2 diabetes: use of oral hypoglycemic agents or insulin OR 2 of the following tests confirming type 2 diabetes: HbA1c >=6.5%; fasting glucose >=7.0 mM; 2-h glucose post 75g oral glucose tolerance test (OGTT) >=11.1 mM) (guidelines.diabetes.ca);) or without diabetes: HbA1c <6.5% AND fasting glucose <7.0 mM; who are awaiting bariatric surgery. Control group: BMI 25.0 to 29.9 kg/m2 (overweight group); without diabetes or prediabetes: HbA1c <6.0% AND fasting glucose <6.1 mM (Diabetes Canada criteria), with a stable weight for the last 3 months. Exclusion Criteria: - bariatric groups: type 1 diabetes; disease (e.g. uncontrolled thyroid disease, malabsorptive or overt inflammatory disorder, metabolic bone disease, creatinine clearance <60 ml/min) or medication (e.g. glucocorticoids, anti-epileptic drugs, osteoporosis therapy and thiazolidinediones) affecting bone metabolism; BMI>60 kg/m2; CT scan impossible to perform (e.g. patient too large for the gantry aperture); pregnant women or women who plan to become pregnant during the study or women of childbearing age who do not agree to take an appropriate contraceptive method during the study; history of oesophageal, gastric or digestive surgery; history of bariatric surgery; cancer at risk of recurrence during the study; Prosthesis that could interfere with interpretation of imaging data; Chronic severe condition or illness precluding from participation in the project. Control group: Same criteria plus: >5% change in weight in the last 3 months; pregnancy or lactation in the last year.

Study Design


Intervention

Procedure:
Bariatric surgery
Sleeve gastrectomy

Locations

Country Name City State
Canada The Research Institute of the McGill University Health Centre Montréal Quebec
Canada Centre de recherche du CHU de Québec - Université Laval Quebec
Canada Centre de recherche de l'IUCPQ Québec

Sponsors (2)

Lead Sponsor Collaborator
CHU de Quebec-Universite Laval McGill University Health Centre/Research Institute of the McGill University Health Centre

Country where clinical trial is conducted

Canada, 

Outcome

Type Measure Description Time frame Safety issue
Other Bone microarchitecture and metabolism by iliac crest bone biopsy after tetracycline labelling using standard histomorphometry during surgery
Other Prevalence and incidence of vertebral fractures (by a CT scout of T4-L5) Using the algorithm-based qualitative method (ABQ) and the Genant method before, 1 year after and 3 years after bariatric surgery
Other Prevalence and incidence of falls by questionnaire before, 1 year after and 3 years after bariatric surgery
Other Prevalence and incidence of non-vertebral fractures by questionnaire (self-reported) before, 1 year after and 3 years after bariatric surgery
Primary Change in volumetric bone mineral density (vBMD) at lumbar spine, hip, tibia and radius assessed by quantitative computed tomography (QCT) before, 1 year after and 3 years after bariatric surgery
Primary Change in areal bone mineral density at lumbar spine, hip and radius assessed by dual-energy X-ray absorptiometry (DXA) before, 1 year after and 3 years after bariatric surgery
Secondary Change in N-terminal propeptide of type 1 procollagen (P1NP) serum bone formation marker before, 4 months after, 8 months after, 1 year after and 3 years after bariatric surgery
Secondary Change in osteocalcin (total, gamma-carboxylated and and under-carboxylated) serum bone formation marker before, 4 months after, 8 months after, 1 year after and 3 years after bariatric surgery
Secondary Change in bone alkaline phosphatase serum bone formation marker before, 4 months after, 8 months after, 1 year after and 3 years after bariatric surgery
Secondary Change in C-telopeptide serum bone resorption marker before, 4 months after, 8 months after, 1 year after and 3 years after bariatric surgery
Secondary Change in fasting glucose diabetes control before, 4 months after, 8 months after, 1 year after and 3 years after bariatric surgery
Secondary Change in HbA1c diabetes control before, 4 months after, 8 months after, 1 year after and 3 years after bariatric surgery
Secondary Change in fasting insulin hormones involved in bone metabolism before, 4 months after, 8 months after, 1 year after and 3 years after bariatric surgery
Secondary Change in serum 25-hydroxyvitamin D hormones involved in bone metabolism before, 4 months after, 8 months after, 1 year after and 3 years after bariatric surgery
Secondary Change in parathormone (PTH) hormones involved in bone metabolism before, 4 months after, 8 months after, 1 year after and 3 years after bariatric surgery
Secondary Change in estradiol and estrone hormones involved in bone metabolism before, 4 months after, 8 months after, 1 year after and 3 years after bariatric surgery
Secondary Change in insulin like growth factor (IGF)-1 hormones involved in bone metabolism before, 4 months after, 8 months after, 1 year after and 3 years after bariatric surgery
Secondary Change in sclerostin hormones involved in bone metabolism before, 4 months after, 8 months after, 1 year after and 3 years after bariatric surgery
Secondary Change in adiponectin hormones involved in bone metabolism before, 4 months after, 8 months after, 1 year after and 3 years after bariatric surgery
Secondary Change in leptin hormones involved in bone metabolism before, 4 months after, 8 months after, 1 year after and 3 years after bariatric surgery
Secondary Change in peptide YY (PYY) hormones involved in bone metabolism before, 4 months after, 8 months after, 1 year after and 3 years after bariatric surgery
Secondary Change in ghrelin hormones involved in bone metabolism before, 4 months after, 8 months after, 1 year after and 3 years after bariatric surgery
Secondary Change in oxidative stress markers hormones involved in bone metabolism before, 4 months after, 8 months after, 1 year after and 3 years after bariatric surgery
Secondary Change in serum advanced glycation end products (AGEs) hormones involved in bone metabolism before, 4 months after, 8 months after, 1 year after and 3 years after bariatric surgery
Secondary Change in Free fatty acids (FFA) hormones involved in bone metabolism before, 4 months after, 8 months after, 1 year after and 3 years after bariatric surgery
Secondary Change in fat and lean mass body composition assessed by bioimpedance and by DXA before, 1 year after and 3 years after bariatric surgery
Secondary Change in visceral and subcutaneous adipose tissue body composition assessed by computed tomography (CT) before, 1 year after and 3 years after bariatric surgery
Secondary Change in muscle mass and fat content at mid-femur assessed by computed tomography (CT) before, 1 year after and 3 years after bariatric surgery
Secondary Change in upper extremity muscle strength assessed by hand grip strength before, 1 year after and 3 years after bariatric surgery
Secondary Change in lower extremity muscle strength assessed by knee extensor strength before, 1 year after and 3 years after bariatric surgery
Secondary Change in muscle function assessed by timed up and go test before, 1 year after and 3 years after bariatric surgery
Secondary Change in physical capacity assessed by 6-minute walk test before, 1 year after and 3 years after bariatric surgery
Secondary Change in balance assessed by Fullerton Advanced Balance (FAB) Scale before and 1 year after bariatric surgery
Secondary Change in sociodemographic factors questionnaire before, 1 year after and 3 years after bariatric surgery
Secondary Change in nutrition 3 web-based 24-h recalls before, 4 months after, 8 months after, 1 year after and 3 years after bariatric surgery
Secondary Change in self-reported physical activity level by questionnaire before, 4 months after, 8 months after, 1 year after and 3 years after bariatric surgery
Secondary Change in measured physical activity level by accelerometer before, 1 year after and 3 years after bariatric surgery
Secondary Change in gut microbiota stool sample before, 1 year after and 3 years after bariatric surgery
Secondary Change in cutaneous Advanced glycation end products (AGEs) skin autofluorescence before, 4 months after, 8 months after, 1 year after and 3 years after bariatric surgery
See also
  Status Clinical Trial Phase
Active, not recruiting NCT05666479 - CGM Monitoring in T2DM Patients Undergoing Orthopaedic Replacement Surgery
Completed NCT05647083 - The Effect of Massage on Diabetic Parameters N/A
Active, not recruiting NCT05661799 - Persistence of Physical Activity in People With Type 2 Diabetes Over Time. N/A
Completed NCT03686722 - Effect of Co-administration of Metformin and Daclatasvir on the Pharmacokinetis and Pharmacodynamics of Metformin Phase 1
Completed NCT02836704 - Comparison of Standard vs Higher Starting Dose of Insulin Glargine in Chinese Patients With Type 2 Diabetes (Glargine Starting Dose) Phase 4
Completed NCT01819129 - Efficacy and Safety of FIAsp Compared to Insulin Aspart in Combination With Insulin Glargine and Metformin in Adults With Type 2 Diabetes Phase 3
Completed NCT04562714 - Impact of Flash Glucose Monitoring in People With Type 2 Diabetes Using Non-Insulin Antihyperglycemic Therapy N/A
Completed NCT02009488 - Treatment Differences Between Canagliflozin and Placebo in Insulin Secretion in Subjects With Type 2 Diabetes Mellitus (T2DM) Phase 1
Completed NCT05896319 - Hyaluronic Acid Treatment of the Post-extraction Tooth Socket Healing in Subjects With Diabetes Mellitus Type 2 N/A
Recruiting NCT05598203 - Effect of Nutrition Education Groups in the Treatment of Patients With Type 2 Diabetes N/A
Completed NCT05046873 - A Research Study Looking Into Blood Levels of Semaglutide and NNC0480-0389 When Given in the Same Injection or in Two Separate Injections in Healthy People Phase 1
Completed NCT04030091 - Pulsatile Insulin Infusion Therapy in Patients With Type 1 and Type 2 Diabetes Mellitus Phase 4
Terminated NCT04090242 - Impact of App Based Diabetes Training Program in Conjunction With the BD Nano Pen Needle in People With T2 Diabetes N/A
Completed NCT03604224 - A Study to Observe Clinical Effectiveness of Canagliflozin 300 mg Containing Treatment Regimens in Indian Type 2 Diabetes Participants With BMI>25 kg/m^2, in Real World Clinical Setting
Completed NCT03620357 - Continuous Glucose Monitoring & Management In Type 2 Diabetes (T2D) N/A
Completed NCT01696266 - An International Survey on Hypoglycaemia Among Insulin-treated Patients With Diabetes
Completed NCT03620890 - Detemir Versus NPH for Type 2 Diabetes Mellitus in Pregnancy Phase 4
Withdrawn NCT05473286 - A Research Study Looking at How Oral Semaglutide Works in People With Type 2 Diabetes in Germany, as Part of Local Clinical Practice
Not yet recruiting NCT05029804 - Effect of Walking Exercise Training on Adherence to Disease Management and Metabolic Control in Diabetes N/A
Completed NCT04531631 - Effects of Dorzagliatin on 1st Phase Insulin and Beta-cell Glucose Sensitivity in T2D and Monogenic Diabetes Phase 2